PMID- 22807982
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240318
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 4
IP  - 1
DP  - 2012 Jul
TI  - Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on 
      proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.
PG  - 168-174
AB  - This study was designed to investigate the effects of a cyclooxygenase (COX)-1 
      inhibitor, SC-560, administered in combination with taxol, on the molecular 
      mechanisms of antitumor efficacy in a SKOV-3 human ovarian carcinoma cell 
      xenograft-bearing mouse model. The mice were treated with 6 mg/kg/day SC-560 by 
      gavage twice every other day and 20 mg/kg taxol by intraperitoneal injection once 
      a week for three weeks. Microvessel density (MVD) and vascular endothelial growth 
      factor (VEGF) mRNA levels of ovarian cancer were detected in the tumor tissues 
      using immunohistochemistry and reverse transcription-polymerase chain reaction 
      (RT-PCR), respectively. The index of proliferating and apoptotic cells in the 
      tumor tissues was determined by staining for Ki-67 and using the terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method, 
      respectively. On day 7 after the end of administration, the tumor volume of mice 
      in the combination group was reduced by 55.35% compared with that of the control 
      mice, and the difference was statistically significant (P<0.05). In the 
      combination group, the expression of VEGF, MVD and the cell proliferation index 
      were inhibited significantly, while the apoptotic index was notably increased 
      (all P<0.01, compared with the control group). Our results indicate that the 
      molecular mechanisms of the antitumor efficacy of SC-560 combined with taxol 
      therapy may act in part by inhibiting tumor angiogenesis, reducing cell 
      proliferation and inducing cell apoptosis.
FAU - Li, Wei
AU  - Li W
AD  - Department of Gynecology, Nanjing Medical University of Hangzhou Hospital, 
      Hangzhou, Zhejiang 310006, P.R. China.
FAU - Liu, Mei-Lin
AU  - Liu ML
FAU - Cai, Jia-Hui
AU  - Cai JH
FAU - Tang, Yun-Xian
AU  - Tang YX
FAU - Zhai, Ling-Yun
AU  - Zhai LY
FAU - Zhang, Jun
AU  - Zhang J
LA  - eng
PT  - Journal Article
DEP - 20120423
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC3398363
EDAT- 2012/07/19 06:00
MHDA- 2012/07/19 06:01
PMCR- 2012/04/23
CRDT- 2012/07/19 06:00
PHST- 2012/01/19 00:00 [received]
PHST- 2012/04/13 00:00 [accepted]
PHST- 2012/07/19 06:00 [entrez]
PHST- 2012/07/19 06:00 [pubmed]
PHST- 2012/07/19 06:01 [medline]
PHST- 2012/04/23 00:00 [pmc-release]
AID - ol-04-01-0168 [pii]
AID - 10.3892/ol.2012.688 [doi]
PST - ppublish
SO  - Oncol Lett. 2012 Jul;4(1):168-174. doi: 10.3892/ol.2012.688. Epub 2012 Apr 23.